Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

70/433 Publications

Cirrhosis Clear all
  1. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023

    FibroTest Other

  2. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022

    FibroTest Alcohol HBV HCV +1

  3. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021

    FibroTest HCV

  4. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review

    Surial B et al. · Liver Int · 2021

    FibroTest HBV

  5. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021

    ActiTest FibroTest HCV

  6. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.

    Majumdar A et al. · Hepatology · 2020

    FibroTest

  7. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.

    Zarski JP et al. · Clin Res Hepatol Gastroenterol · 2020

    ActiTest FibroTest HCV

  8. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020

    FibroTest Other

  9. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019

    FibroTest NashTest SteatoTest HIV

  10. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019

    FibroTest Alcohol

  11. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019

    FibroTest Alcohol

  12. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    ActiTest FibroTest NashTest NashTest-2 +3

  13. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018

    ActiTest FibroTest SteatoTest Metabolic

  14. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018

    ActiTest FibroTest HBV

  15. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017

    FibroTest HBV

  16. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017

    FibroTest Other

  17. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017

    FibroTest HCV

  18. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017

    FibroTest Alcohol

  19. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016

    ActiTest FibroTest SteatoTest Metabolic

  20. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016

    FibroTest HCV

  21. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016

    FibroTest HBV HCV

  22. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016

    FibroTest HBV HCV HIV

  23. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015

    ActiTest FibroTest Alcohol HBV +3

  24. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015

    FibroTest Alcohol HBV HCV +3

  25. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015

    ActiTest FibroTest HBV

  26. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015

    FibroTest HBV HCV

  27. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015

    FibroTest Alcohol HBV HCV +1

  28. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015

    ActiTest AshTest FibroTest NashTest +2

  29. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015

    FibroTest Alcohol

  30. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014

    FibroTest HBV

  31. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014

    FibroTest HCV

  32. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014

    FibroTest Alcohol

  33. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

    Castera L et al. · HIV Med · 2014

    FibroTest HCV HIV

  34. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014

    FibroTest HBV

  35. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014

    FibroTest HBV

  36. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014

    FibroTest HBV HCV

  37. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014

    FibroTest HCV

  38. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014

    FibroTest HBV

  39. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    Leroy V et al. · J Hepatol · 2014

    FibroTest HBV HCV

  40. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014

    FibroTest Other

  41. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014

    ActiTest FibroTest HBV

  42. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014

    FibroTest HCV

  43. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014

    FibroTest HBV

  44. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

    Poynard T et al. · Ann Intern Med · 2013

    FibroTest HCV

  45. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013

    FibroTest HCV

  46. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013

    FibroTest Alcohol HBV HCV +3

  47. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013

    FibroTest Alcohol HBV HCV +2

  48. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013

    FibroTest HBV HIV

  49. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013

    FibroTest HCV

  50. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.

    Chen J et al. · J Clin Lab Anal · 2013

    FibroTest HBV

  51. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012

    FibroTest Alcohol HBV HCV +3

  52. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012

    ActiTest FibroTest HBV

  53. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012

    Metabolic

  54. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012

    FibroTest Alcohol

  55. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011

    FibroTest HBV HCV HIV

  56. Noninvasive assessment of portal hypertension in patients with cirrhosis.

    Thabut D et al. · Hepatology · 2011

    FibroTest Alcohol HBV HCV +3

  57. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011

    FibroTest HBV HCV HIV +1

  58. Diagnosis of fibrosis and cirrhosis. Liver biopsy is not always necessary.

    · Prescrire Int · 2010

    FibroTest HCV

  59. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010

    FibroTest HBV HCV HIV

  60. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010

    FibroTest HCV

  61. The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".

    Munteanu M et al. · Gastroenterol Clin Biol · 2009

    FibroTest HCV

  62. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.

    Calès P et al. · Gastroenterol Clin Biol · 2008

    FibroTest HCV

  63. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007

    ActiTest AshTest FibroTest NashTest +7

  64. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007

    FibroTest Alcohol HBV HCV +2

  65. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.

    Thabut D et al. · Liver Int · 2006

    FibroTest Alcohol HBV HCV

  66. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001

    FibroTest HCV

  67. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997

    HCV

  68. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    FibroTest HBV

  69. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    FibroTest HCV

  70. Ministère des Affaires Sociales et de la Santé Key publication

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.